F-star

F-star Biotechnology Ltd. is a biotechnology company, founded in Vienna in 2006,[1] with a current main research site in Cambridge, UK. The company is focused in developing bispecific monoclonal antibodies using a modular combinatorial approach that engineers the Fc constant region of an immunoglobulin into a novel antigen-binding site.[2][3]

F-star Biotechnology Ltd.
IndustryPharmaceutical
HeadquartersCambridge, UK
Websitewww.f-star.com

See also
  1. "F-star starts its operations" (PDF). F-Star. 12 June 2006. Retrieved 12 December 2016.
  2. "Home". f-star.com.
  3. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, Himmler G, Mudde GC, Rüker F (2010). "Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties". Protein Eng Des. 23 (4): 289–297. doi:10.1093/protein/gzq005. PMID 20150180.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.